MA32288B1 - Nouveaux anticorps utiles pour le traitement du cancer - Google Patents

Nouveaux anticorps utiles pour le traitement du cancer

Info

Publication number
MA32288B1
MA32288B1 MA33315A MA33315A MA32288B1 MA 32288 B1 MA32288 B1 MA 32288B1 MA 33315 A MA33315 A MA 33315A MA 33315 A MA33315 A MA 33315A MA 32288 B1 MA32288 B1 MA 32288B1
Authority
MA
Morocco
Prior art keywords
antibodies
relates
cancer treatment
antibodies useful
new antibodies
Prior art date
Application number
MA33315A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-François Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32288B1 publication Critical patent/MA32288B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention est relative à de nouveaux anticorps capables de se lier spécifiquement à la protéine humaine cd 151, notamment monoclonaux d'origine murine, chimériques et humanisés, ainsi que les séquences d'acide aminé et nucléiques codant pour ces anticorps. L'invention comprend également l'utilisation de ces anticorps à titre de médicament pour le traitement prophylactique et/ou thérapeutique de cancers ainsi que dans des procédés ou nécessaire de diagnostic de maladies liées à la surexpression de la protéine cd151. L'invention comprend enfin des produits et/ou des compositions comprenant de tels anticorps en association avec des anticorps et/ou des agents anticancéreux ou conjugués avec des toxines et./ou des radioéléments et leur utilisation pour la prévention et/ou le traitement de certains cancers.
MA33315A 2008-04-11 2010-11-03 Nouveaux anticorps utiles pour le traitement du cancer MA32288B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801985A FR2929946B1 (fr) 2008-04-11 2008-04-11 Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
PCT/FR2009/050612 WO2009136070A1 (fr) 2008-04-11 2009-04-08 Nouveaux anticorps utiles pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA32288B1 true MA32288B1 (fr) 2011-05-02

Family

ID=39645493

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33315A MA32288B1 (fr) 2008-04-11 2010-11-03 Nouveaux anticorps utiles pour le traitement du cancer

Country Status (23)

Country Link
US (3) US8198413B2 (fr)
EP (1) EP2268671A1 (fr)
JP (1) JP2011517565A (fr)
KR (1) KR20110010708A (fr)
CN (1) CN102027014A (fr)
AR (1) AR071304A1 (fr)
AU (1) AU2009245587B2 (fr)
BR (1) BRPI0909016A2 (fr)
CA (1) CA2720904A1 (fr)
CL (1) CL2009000862A1 (fr)
CO (1) CO6311009A2 (fr)
FR (1) FR2929946B1 (fr)
GE (1) GEP20135826B (fr)
IL (1) IL208595A0 (fr)
MA (1) MA32288B1 (fr)
MX (1) MX2010011147A (fr)
NZ (1) NZ588887A (fr)
RU (1) RU2010145063A (fr)
SA (1) SA109300216B1 (fr)
TW (1) TW201002347A (fr)
UA (1) UA105630C2 (fr)
WO (1) WO2009136070A1 (fr)
ZA (1) ZA201007751B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929519B1 (fr) * 2008-04-04 2010-04-23 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement precoce des cancers.
EP2308897A1 (fr) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer
AU2012214274B2 (en) * 2011-02-11 2017-02-02 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
WO2012131680A2 (fr) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions et procédés pour le traitement de l'inflammation
FR3017936B1 (fr) 2014-02-21 2019-03-15 Thales Systeme de regulation thermique d'au moins un module electronique embarque a bord d'un aeronef
AU2016348391A1 (en) * 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
ITUB20154769A1 (it) 2015-11-04 2017-05-04 Centro Di Riferimento Oncologico Cro Irccs Aviano Anticorpo monoclonale anti-BARF1
MX2020009522A (es) 2018-03-13 2020-10-22 Phanes Therapeutics Inc Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CN113164633B (zh) * 2018-10-09 2023-11-21 艾比克斯生物科学公司 针对细丝蛋白-a的抗体及其治疗用途
WO2023235666A2 (fr) * 2022-05-31 2023-12-07 Vanderbilt University Anticorps humains contre bordetella pertussis et leurs utilisations
CN114790240B (zh) * 2022-06-10 2023-06-06 郑州大学 SARS-CoV-2中和性单克隆抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US20080003605A1 (en) * 2006-05-24 2008-01-03 The University Of Chicago Microarray analysis of light chain variable gene expression and methods of use
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Also Published As

Publication number Publication date
GEP20135826B (en) 2013-05-27
FR2929946B1 (fr) 2010-05-28
BRPI0909016A2 (pt) 2015-12-22
SA109300216B1 (ar) 2013-04-20
ZA201007751B (en) 2011-08-31
FR2929946A1 (fr) 2009-10-16
US8697855B2 (en) 2014-04-15
IL208595A0 (en) 2010-12-30
NZ588887A (en) 2012-10-26
AU2009245587A1 (en) 2009-11-12
CA2720904A1 (fr) 2009-11-12
MX2010011147A (es) 2011-10-10
CO6311009A2 (es) 2011-08-22
US20120284810A1 (en) 2012-11-08
CL2009000862A1 (es) 2009-08-14
AU2009245587B2 (en) 2014-11-27
US20140193329A1 (en) 2014-07-10
TW201002347A (en) 2010-01-16
KR20110010708A (ko) 2011-02-07
JP2011517565A (ja) 2011-06-16
EP2268671A1 (fr) 2011-01-05
CN102027014A (zh) 2011-04-20
AR071304A1 (es) 2010-06-09
RU2010145063A (ru) 2012-05-20
WO2009136070A1 (fr) 2009-11-12
UA105630C2 (uk) 2014-06-10
US8198413B2 (en) 2012-06-12
US20100150902A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
NL301089I2 (nl) imlifidase
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
MX2014005244A (es) Proteina de enlace de antigeno y su uso como producto de direccionamiento para tratamiento del cancer.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
UA116874C2 (uk) Імунокон'югат анти-мезотеліну
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
IN2015DN02349A (fr)
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
MX2021002144A (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
WO2008042941A3 (fr) Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse
WO2007007152A3 (fr) Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer